Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2005

01-02-2005 | Review Article

Acute emesis: moderately emetogenic chemotherapy

Authors: Jørn Herrstedt, Jim M. Koeller, Fausto Roila, Paul J. Hesketh, David Warr, Cynthia Rittenberg, Mario Dicato

Published in: Supportive Care in Cancer | Issue 2/2005

Login to get access

Abstract

This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the Perugia Consensus Conference, which took place at the end of March 2004. The review focuses on new studies appearing since the last consensus conference in 1997. The following issues are addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin (5-HT3)-receptor antagonists, dopamine D2 receptor antagonists, and neurokinin (NK1) receptor antagonists. Antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy is also reviewed. Consensus statements are given, including optimal dose and schedule of 5-HT3-receptor antagonists and of dexamethasone. The new 5-HT3-receptor antagonist, palonosetron, is a reasonable alternative to the well-established agents of this class—ondansetron, granisetron, tropisetron and dolasetron. It is concluded that the best prophylaxis in patients receiving moderately emetogenic chemotherapy is still the combination of one of the 5-HT3-receptor antagonists and dexamethasone. The results of studies adding a NK1-receptor antagonist to this combination are awaited and might change future recommendations.
Appendix
Available only for authorised users
Literature
1.
Adams M, Soukop M, Barley V, et al (1995) Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. Anticancer Drugs 6:514–521PubMed
2.
Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRefPubMed
3.
ASHP Commission on Therapeutics (1999) ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56:729–764PubMed
4.
Beck TM, York M, Chang A, et al (1997) Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest 15:297–303PubMed
5.
Du Bois A, McKenna CJ, Andersson H, Lahousen M, Kitchener H, Pinter T, Capstick V, Wilkinson JR (1997) A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology 54:7–14
6.
Davidson NG, Paska W, Van Belle S, Goedhals L, McQuade B, McRae J (1997) Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository Emesis Study Group. Oncology 54:380–386PubMed
7.
Davidson N, Rapoport B, Erikstein B, et al (1999) Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 21:492–502CrossRefPubMed
8.
Eisenberg P, Figueroa-Vadillo J, Zamora R, et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3-receptor antagonist. Cancer 98:2473–2482CrossRefPubMed
9.
ESMO Guidelines Task Force (2001) ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Ann Oncol 12:1059–1060CrossRefPubMed
10.
Fujii M, Kanke M, Arai Y, et al (2000) A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin. Gan To Kagaku Ryoho 27:1557–1563PubMed
11.
Goldschmidt H, Salwender H, Egerer G, Kempe R, Voigt T (1997) Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy. Anticancer Drugs 8:436–444PubMed
12.
Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994PubMed
13.
Gralla R, Lichinitser M, Van der Vegt S, et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577CrossRefPubMed
14.
Griffin AM, Butow PN, Coates AS, et al (1996) On the receiving end V: patient perceptions and the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195PubMed
15.
Grunberg SM, Deuson RR, Mavros P, et al (2004) Incidence of chemotherapy-induced nausea and vomiting after modern antiemetics. Cancer 100:2261–2268CrossRefPubMed
16.
Harousseau JL, Zittoun R, Bonneterre J, Hedouin M, Ouvry J (2000) Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination. Bull Cancer 87:491–497PubMed
17.
Herrstedt J, Sigsgaard T, Boesgaard M, Jens TP, Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076–1080CrossRefPubMed
18.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119CrossRefPubMed
19.
Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1–5CrossRefPubMed
20.
Italian Group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide: J Clin Oncol 22:725–729
21.
Jones AL, Hill AS, Soukop M, et al (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338(8765):483–487CrossRefPubMed
22.
Kaizer L, Warr D, Hoskins P, et al (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050–1057PubMed
23.
Kang YK, Park YH, Ryoo BY, et al (2002) Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res 30:220–229PubMed
24.
Lofters WS, Pater JL, Zee B, et al (1997) Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15:2966–2973PubMed
25.
Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C (1998) Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4:52–58PubMed
26.
Perez EA, Hesketh P, Sandbach J, et al (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760PubMed
27.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMed
28.
Sigsgaard T, Herrstedt J, Andersen LJ, et al (1999) Granisetron compared with prednisolone plus metopimazine as antiemetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 80:412–418CrossRefPubMed
29.
Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, Dombernowsky P (2001) Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 19:2091–2097PubMed
30.
Soukop M, McQuade B, Hunter E, et al (1992) Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295–304PubMed
31.
Warr D, Willan A, Fine S, et al (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 1169–1173
32.
de Wit R, Schmith PIM, Verweij J, et al (1996) Analysis of cumulative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 14:644–651PubMed
Metadata
Title
Acute emesis: moderately emetogenic chemotherapy
Authors
Jørn Herrstedt
Jim M. Koeller
Fausto Roila
Paul J. Hesketh
David Warr
Cynthia Rittenberg
Mario Dicato
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 2/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0701-7

Other articles of this Issue 2/2005

Supportive Care in Cancer 2/2005 Go to the issue

Review Article

Emesis induced by low or minimal emetic risk chemotherapy

Review Article

Delayed emesis: moderately emetogenic chemotherapy

Original Article

Anticipatory nausea and vomiting

Review Article

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

Original Article

The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

Forthcoming Meetings

Forthcoming Meetings February 2005
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits